Joshua Z Drago1, Mithat Gönen2, Gita Thanarajasingam3, Chana A Sacks4, Michael J Morris1,5, Philip W Kantoff1,5, Konrad H Stopsack1. 1. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA. 4. Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA. 5. Weill Cornell Medical College, New York, NY, USA.
Abstract
BACKGROUND: Safety is a central consideration when choosing between multiple medications with similar efficacy. We aimed to evaluate whether adverse event (AE) profiles of 3 such drugs in advanced prostate cancer could be distinguished based on published literature. METHODS: We assessed consistency in AE reporting, AE risk in placebo arms, and methodology used for risk estimates and quantification of statistical uncertainty in randomized placebo-controlled phase III trials of apalutamide, enzalutamide, and darolutamide in advanced prostate cancer. RESULTS: Seven included clinical trials enrolled a total of 9215 participants (range = 1051-1715 per trial) across 3 prostate cancer disease states. Within disease states, baseline patient characteristics appeared similar between trials. Of 54 distinct AE types in total, only 3 (fatigue, hypertension, and seizure) were reported by all 7 trials. Absolute risks of AEs in the placebo arms differed systematically and more than twofold between trials, which was associated with visit frequency and resulted in different degrees of uncertainty in AE profiles between trials. No trial used inferential methodology to quantify statistical uncertainty in AE risks, but 6 of 7 trials drew overall conclusions. Two trials concluded that there was no elevated AE risk because of the intervention, including the trial of darolutamide, which had the greatest statistical uncertainty. CONCLUSIONS: Rigorous comparison of drug safety was precluded by heterogeneity in AE reporting, variation in AE risks in the placebo arms, and lack of inferential statistical methodology, underscoring considerable opportunities to improve how AE data are collected, analyzed, and interpreted in oncology trials.
BACKGROUND: Safety is a central consideration when choosing between multiple medications with similar efficacy. We aimed to evaluate whether adverse event (AE) profiles of 3 such drugs in advanced prostate cancer could be distinguished based on published literature. METHODS: We assessed consistency in AE reporting, AE risk in placebo arms, and methodology used for risk estimates and quantification of statistical uncertainty in randomized placebo-controlled phase III trials of apalutamide, enzalutamide, and darolutamide in advanced prostate cancer. RESULTS: Seven included clinical trials enrolled a total of 9215 participants (range = 1051-1715 per trial) across 3 prostate cancer disease states. Within disease states, baseline patient characteristics appeared similar between trials. Of 54 distinct AE types in total, only 3 (fatigue, hypertension, and seizure) were reported by all 7 trials. Absolute risks of AEs in the placebo arms differed systematically and more than twofold between trials, which was associated with visit frequency and resulted in different degrees of uncertainty in AE profiles between trials. No trial used inferential methodology to quantify statistical uncertainty in AE risks, but 6 of 7 trials drew overall conclusions. Two trials concluded that there was no elevated AE risk because of the intervention, including the trial of darolutamide, which had the greatest statistical uncertainty. CONCLUSIONS: Rigorous comparison of drug safety was precluded by heterogeneity in AE reporting, variation in AE risks in the placebo arms, and lack of inferential statistical methodology, underscoring considerable opportunities to improve how AE data are collected, analyzed, and interpreted in oncology trials.
Authors: John P A Ioannidis; Stephen J W Evans; Peter C Gøtzsche; Robert T O'Neill; Douglas G Altman; Kenneth Schulz; David Moher Journal: Ann Intern Med Date: 2004-11-16 Impact factor: 25.391
Authors: Kim N Chi; Neeraj Agarwal; Anders Bjartell; Byung Ha Chung; Andrea J Pereira de Santana Gomes; Robert Given; Álvaro Juárez Soto; Axel S Merseburger; Mustafa Özgüroğlu; Hirotsugu Uemura; Dingwei Ye; Kris Deprince; Vahid Naini; Jinhui Li; Shinta Cheng; Margaret K Yu; Ke Zhang; Julie S Larsen; Sharon McCarthy; Simon Chowdhury Journal: N Engl J Med Date: 2019-05-31 Impact factor: 91.245
Authors: Daniel H Solomon; Robert J Glynn; Elizabeth W Karlson; Fengxin Lu; Cassandra Corrigan; Josh Colls; Chang Xu; Jean MacFadyen; Medha Barbhaiya; Nancy Berliner; Paul F Dellaripa; Brendan M Everett; Aruna D Pradhan; Sarah P Hammond; Meredith Murray; Deepak A Rao; Susan Y Ritter; Anna Rutherford; Jeffrey A Sparks; Jackie Stratton; Dong H Suh; Sara K Tedeschi; Kathleen M M Vanni; Nina P Paynter; Paul M Ridker Journal: Ann Intern Med Date: 2020-02-18 Impact factor: 25.391
Authors: Paul G Kluetz; Bindu Kanapuru; Steven Lemery; Laura Lee Johnson; Mallorie H Fiero; Karen Arscott; Yolanda Barbachano; Ethan Basch; Michelle Campbell; Joseph C Cappelleri; David Cella; Charles Cleeland; Corneel Coens; Selena Daniels; Crystal S Denlinger; Dianne L Fairclough; James R Hillard; Lori Minasian; Sandra A Mitchell; Daniel O'Connor; Sheetal Patel; Eric H Rubin; Anna Ryden; Katherine Soltys; Rajeshwari Sridhara; Gita Thanarajasingam; Galina Velikova; Stephen Joel Coons Journal: Value Health Date: 2017-11-07 Impact factor: 5.725
Authors: David A Dorr; Rachel Burdon; Dennis P West; Jennifer Lagman; Christina Georgopoulos; Steven M Belknap; June M McKoy; Benjamin Djulbegovic; Beatrice J Edwards; Sigmund A Weitzman; Simone Boyle; Martin S Tallman; Moshe Talpaz; Oliver Sartor; Charles L Bennett Journal: Clin Cancer Res Date: 2009-05-19 Impact factor: 12.531
Authors: Karim Fizazi; Neal Shore; Teuvo L Tammela; Albertas Ulys; Egils Vjaters; Sergey Polyakov; Mindaugas Jievaltas; Murilo Luz; Boris Alekseev; Iris Kuss; Christian Kappeler; Amir Snapir; Toni Sarapohja; Matthew R Smith Journal: N Engl J Med Date: 2019-02-14 Impact factor: 176.079
Authors: Michael Brave; Chana Weinstock; Jamie R Brewer; Dow-Chung Chi; Daniel L Suzman; Joyce Cheng; Lijun Zhang; Rajeshwari Sridhara; Amna Ibrahim; Paul G Kluetz; Richard Pazdur; Julia A Beaver Journal: Clin Cancer Res Date: 2020-04-13 Impact factor: 12.531
Authors: Gillian Gresham; Márcio A Diniz; Zahra S Razaee; Michael Luu; Sungjin Kim; Ron D Hays; Steven Piantadosi; Mourad Tighiouart; Greg Yothers; Patricia A Ganz; André Rogatko Journal: J Natl Cancer Inst Date: 2020-12-14 Impact factor: 13.506
Authors: Paul G Kluetz; Bellinda L King-Kallimanis; Daniel Suzman; Elaine Chang; Michael M Brave; Chana Weinstock; Vishal Bhatnagar; Julia A Beaver; Meredith K Chuk Journal: J Natl Cancer Inst Date: 2021-05-04 Impact factor: 13.506